Stockscreener 앱 받기
0.432
7.22%
-0.0336
시간 외 거래:
.43
-0.002
-0.46%
전일 마감가:
$0.4656
열려 있는:
$0.4601
하루 거래량:
172.31K
Relative Volume:
0.11
시가총액:
$6.00M
수익:
$19.57M
순이익/손실:
$-25.12M
주가수익비율:
-0.1869
EPS:
-2.3114
순현금흐름:
$-19.71M
1주 성능:
-4.68%
1개월 성능:
-32.38%
6개월 성능:
-79.03%
1년 성능:
-93.52%
1일 변동 폭
$0.4302
$0.4605
1주일 범위
$0.4302
$0.4835
52주 변동 폭
$0.383
$7.95
비보스 테라퓨틱스 Stock (VVOS) Company Profile
명칭
Vivos Therapeutics Inc
전화
(866)908-4867
주소
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
0.432 | 6.00M | 19.57M | -25.12M | -19.71M | -2.3114 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
비보스 테라퓨틱스 주식(VVOS)의 최신 뉴스
Price to earnings forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView
Vivos Therapeutics (VVOS) Slides 6.87% as Bearish Pressure Tests Critical SupportCovered Call Trade - dars.gov.et
Vivos Therapeutics Announces Securities Purchase Agreement and Registration Rights for PIPE Financing - Minichart
Vivos Therapeutics Creates New Series A Preferred Stock - TipRanks
Vivos Therapeutics Raises $2.1 Million in PIPE With V-Co 4 and Bigger Capital - TradingView
Vivos Therapeutics (VVOS) completes $2.1M PIPE with preferred stock and warrants - Stock Titan
Enterprise value to EBITDA forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView
VVOSVivos Therapeutics Inc Latest SEC Filings - Finviz
Vivos Therapeutics (VVOS) Stock Sees Fair Value Moves Lower As Analysts Reset Growth Assumptions - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants - The Manila Times
Vivos says its Vida appliance improved insomnia in all 37 patients - Stock Titan
Vivos Therapeutics, Inc. announced that it has received $1 million in funding - marketscreener.com
VIVOS THERAPEUTICS INC (VVOS) Stock Chart - ChartMill
Vivos Therapeutics, Inc. Actuals & Estimates (NASDAQ:VVOS) - TradingView
Vivos Therapeutics Extends Debt-for-Equity Conversion Timeline - TipRanks
Vivos (NASDAQ: VVOS) extends Streeterville $4.5M debt-for-equity pact - Stock Titan
Vivos Therapeutics Enters Debt-for-Equity Deal, Extends $2.6M Financing Deadline With Streeterville - TradingView
VVOS Forecast — Price Target — Prediction for 2027 - TradingView
Vivos Therapeutics Inc (VVOS) Institutional Confidence - TradingKey
VVOS Q1 2026 Earnings: EPS Misses Estimates as Stock Surges on Operational ProgressEarnings Revision Upgrade - dars.gov.et
Vivos extends debt conversion deadline with Streeterville to August - Investing.com UK
Vivos extends debt conversion deadline with Streeterville to August By Investing.com - Investing.com Australia
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity - marketscreener.com
Vivos gets more time to convert $4.5M debt into equity - Stock Titan
Vivos Therapeutics Inc (VVOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vivos Therapeutics Inc (VVOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vivos Therapeutics Inc (VVOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vivos Therapeutics Inc (VVOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vivos Therapeutics Inc (VVOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vivos Therapeutics Inc (VVOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vivos Therapeutics Inc (VVOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vivos Therapeutics (VVOS) Slides 6% as Selling Pressure Intensifies Near Key SupportForce Index - dars.gov.et
Vivos Therapeutics Plans Rights Offering to Existing Shareholders - TipRanks
Vivos Therapeutics (NASDAQ: VVOS) outlines proposed tradable rights offering terms - Stock Titan
Vivos Therapeutics Partners with Florida Cardiology Group to Expand Sleep Apnea and Insomnia Treatment for Cardiovascular Patients – Minichart - Minichart
Vivos Therapeutics Forms AIM Florida Sleep Care Venture - TipRanks
Vivos Therapeutics (NASDAQ: VVOS) inks AIM Florida deal with major cardiology group - Stock Titan
Vivos Therapeutics Inc. (VVOS) Q1 2026 Earnings: EPS Misses Estimates as Stock DeclinesLong-Term Guidance - lwvtexas.org
Vivos Therapeutics Plans to File for Proposed Rights Offering - Moomoo
Vivos Therapeutics plans rights offering for shareholders By Investing.com - Investing.com South Africa
Vivos Therapeutics plans rights offering for shareholders - Investing.com
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering - The Manila Times
Vivos plans 9‑month tradable rights for shareholders to buy stock - Stock Titan
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients - The Manila Times
VVOS: Capital-light, scalable sleep apnea treatment model targets rapid, profitable national expansion - TradingView
VVOS: Rapidly scaling sleep apnea treatment with high margins and unique FDA-cleared devices - TradingView
Vivos Therapeutics Restructures Debt to Support Nasdaq Compliance - The Globe and Mail
Vivos Therapeutics, Inc. to Present at The Small Cap Showcase & WTR Insights on June 9, 2026 - Quiver Quantitative
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026 - The Manila Times
Vivos Therapeutics Announces $4.5 Million Debt-to-Equity Exchange Agreement to Support Nasdaq Listing and Strengthen Financial Position – Minichart - Minichart
비보스 테라퓨틱스 (VVOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.36%
자본화:
|
볼륨(24시간):